European regulators have rejected Puma’s breast cancer drug Nerlynx (neratinib) – diverging from the FDA, which opted to grant the drug a licence last year.
MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data g
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.